Published in J Clin Invest on March 01, 2004
Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest (2006) 2.00
The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest (2005) 1.82
LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology (2007) 1.70
The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-κB signaling. Nat Immunol (2012) 1.68
A crucial role for HVEM and BTLA in preventing intestinal inflammation. J Exp Med (2008) 1.67
Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. Immunity (2010) 1.50
Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc Natl Acad Sci U S A (2004) 1.24
Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest (2011) 1.22
Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. J Clin Invest (2006) 1.20
The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol (2013) 1.17
Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling. J Leukoc Biol (2010) 1.15
Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS One (2011) 1.08
Development of immunoglobulin A nephropathy- like disease in beta-1,4-galactosyltransferase-I-deficient mice. Am J Pathol (2007) 1.05
Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunol Rev (2009) 0.98
Neuronal and nonneuronal cholinergic structures in the mouse gastrointestinal tract and spleen. J Comp Neurol (2013) 0.98
New insights into the pathogenesis of IgA nephropathy. Semin Immunopathol (2014) 0.96
Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners. Semin Immunopathol (2009) 0.96
The mucosa-kidney axis in IgA nephropathy. Nat Rev Nephrol (2015) 0.89
IL5RA and TNFRSF6B gene variants are associated with sporadic IgA nephropathy. J Am Soc Nephrol (2008) 0.85
The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition. Pediatr Nephrol (2017) 0.83
Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract. Inmunologia (2007) 0.80
TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease. J Am Soc Nephrol (2016) 0.79
Re-thinking the functions of IgA(+) plasma cells. Gut Microbes (2014) 0.78
Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation. Clin Transl Gastroenterol (2015) 0.76
Disruption of Smad4 expression in T cells leads to IgA nephropathy-like manifestations. PLoS One (2013) 0.76
LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro. Diabetologia (2016) 0.75
Henoch-Schonlein purpura antecedent to Crohn's disease. SAGE Open Med Case Rep (2015) 0.75
Lymphotoxin β receptor signaling induces IL-8 production in human bronchial epithelial cells. PLoS One (2014) 0.75
Immunological phenotype of the murine Lrba knockout. Immunol Cell Biol (2017) 0.75
Peyer's patches: an enriched source of precursors for IgA-producing immunocytes in the rabbit. J Exp Med (1971) 5.83
A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science (2000) 5.78
The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity (1998) 4.56
[Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris) (1968) 4.44
LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity (1998) 4.23
The origin and antigen-dependent distribution of IgA-containing cells in the intestine. J Exp Med (1978) 4.01
In situ class switching and differentiation to IgA-producing cells in the gut lamina propria. Nature (2001) 3.58
Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature (1996) 3.11
Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol (2003) 2.90
Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med (2000) 2.18
Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol (2003) 2.10
Experimental IgA nephropathy. J Exp Med (1979) 2.09
Immunologic studies in IgA nephropathy. Kidney Int (1980) 1.99
Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med (2002) 1.95
Mesenteric lymph as a major source of serum IgA in guinea pigs and rats. Eur J Immunol (1973) 1.90
Transport models for secretory IgA and secretory IgM. Clin Exp Immunol (1981) 1.90
The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest (2001) 1.82
Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice. Eur J Immunol (1997) 1.80
Impaired mucosal immune responses in interleukin 4-targeted mice. J Exp Med (1995) 1.71
Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology (1998) 1.65
Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol (2001) 1.65
The syndrome of IgA nephropathy. Clin Nephrol (1984) 1.37
Signaling via LTbetaR on the lamina propria stromal cells of the gut is required for IgA production. Nat Immunol (2002) 1.36
Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J Exp Med (2001) 1.32
Increased frequency of surface IgA-positive plasma cells in the intestinal lamina propria and decreased IgA excretion in hyper IgA (HIGA) mice, a murine model of IgA nephropathy with hyperserum IgA. J Immunol (2000) 1.25
Altered hepatic transport of immunoglobulin A in mice lacking the J chain. J Exp Med (1995) 1.24
Paradoxical IgA immunity in CD4-deficient mice. Lack of cholera toxin-specific protective immunity despite normal gut mucosal IgA differentiation. J Immunol (1995) 1.14
Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med (2002) 1.10
Protection against cholera toxin after oral immunization is thymus-dependent and associated with intestinal production of neutralizing IgA antitoxin. Scand J Immunol (1987) 1.08
Yersinia enterocolitica and glomerulonephritis. Lancet (1978) 1.01
The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it. BMC Clin Pathol (2001) 1.01
Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol (1996) 1.00
Evidence for a specific IgA receptor in rat and human mesangial cells. J Immunol (1993) 1.00
The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. Eur J Immunol (2002) 0.99
Immunoregulatory factors in the pathogenesis of IgA nephropathy. Kidney Int (1990) 0.98
[Immunoglobulin A glomerular nephropathy associated with inflammatory colitis. Apropos of 2 cases]. Presse Med (1984) 0.94
Requirements for B7-CD28 costimulation in mucosal IgA responses: paradoxes observed in CTLA4-H gamma 1 transgenic mice. J Immunol (1998) 0.93
Idiopathic IgA nephropathy. Kidney Int (1984) 0.91
The pathogenic role of immunoglobulin A polymers in immunoglobulin A nephropathy. Nephron (1993) 0.89
Increased dimeric IgA-producing B cells in tonsils in IgA nephropathy determined by in situ hybridization for J chain mRNA. Clin Exp Immunol (1995) 0.89
Composition of IgA-containing circulating immune complexes in IgA nephropathy. Am J Kidney Dis (1988) 0.86
Systemic and mucosal IgA responses to systemic antigen challenge in IgA nephropathy. Clin Immunol Immunopathol (1993) 0.85
B and T cell abnormalities in patients with primary IgA nephropathy. Kidney Int (1985) 0.84
Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss. Transplantation (1997) 0.79
IgA nephropathy and mucosal immune system. Tokai J Exp Clin Med (1989) 0.78
Finding the missing heritability of complex diseases. Nature (2009) 67.95
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet (2006) 20.76
A global map of p53 transcription-factor binding sites in the human genome. Cell (2006) 20.65
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet (2007) 19.08
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet (2008) 9.52
Inflammatory bowel disease. N Engl J Med (2009) 8.62
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet (2011) 5.58
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol (2006) 4.81
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet (2010) 4.65
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
Adaptive immune cells temper initial innate responses. Nat Med (2007) 3.37
Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host Microbe (2007) 3.34
The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity (2011) 3.32
Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol (2005) 3.22
Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry (2008) 3.16
Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest (2005) 3.15
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
The genetics of inflammatory bowel disease. Gastroenterology (2003) 2.95
L-histidine decarboxylase and Tourette's syndrome. N Engl J Med (2010) 2.92
Recognition of host immune activation by Pseudomonas aeruginosa. Science (2005) 2.84
Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol (2008) 2.84
Promoter choice determines splice site selection in protocadherin alpha and gamma pre-mRNA splicing. Mol Cell (2002) 2.78
A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest (2004) 2.75
Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest (2006) 2.67
A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology (2002) 2.66
Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology (2003) 2.64
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J Cell Sci (2006) 2.59
Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol (2010) 2.47
Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell (2005) 2.46
Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe (2011) 2.46
Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol (2006) 2.44
The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state. J Cell Biol (2008) 2.42
Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology (2008) 2.42
CD95 promotes tumour growth. Nature (2010) 2.42
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature (2012) 2.36
Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet (2003) 2.33
Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev (2002) 2.29
Actin depolymerization disrupts tight junctions via caveolae-mediated endocytosis. Mol Biol Cell (2005) 2.29
Epithelial barriers in homeostasis and disease. Annu Rev Pathol (2010) 2.28
NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut (2011) 2.26
Cannulation of the innominate artery with a side graft in arch surgery. Ann Thorac Surg (2010) 2.24
Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet (2004) 2.23
Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med (2002) 2.23
Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med (2010) 2.22
Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci U S A (2007) 2.20
Evaluation of toxicological monitoring markers using proteomic analysis in rats exposed to formaldehyde. J Proteome Res (2006) 2.17
Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J Exp Med (2009) 2.12
Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest (2011) 2.09
Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science (2007) 2.06
Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity (2013) 2.01
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Continuing attrition of physician-scientists (CAPS): a preventable syndrome? Gastroenterology (2012) 2.00
Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest (2006) 2.00
Hereditary neuropathy with liability to pressure palsy: an investigation in a rare and large Chinese family. Eur Neurol (2012) 1.99
Lymphotoxin regulates commensal responses to enable diet-induced obesity. Nat Immunol (2012) 1.99
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med (2010) 1.97
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med (2003) 1.92
Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer (2008) 1.89
IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology (2006) 1.89
p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol (2005) 1.86
IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med (2009) 1.85
Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology (2008) 1.84
Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol (2006) 1.83
The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest (2005) 1.82
Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol (2006) 1.79
Lymphotoxin pathway directs thymic Aire expression. Nat Immunol (2003) 1.79
Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One (2011) 1.79
Toward simpler and faster genome-wide mutagenesis in mice. Nat Genet (2007) 1.77
Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol (2008) 1.76
Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology (2015) 1.76
The Tlx gene regulates the timing of neurogenesis in the cortex. J Neurosci (2004) 1.75
Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem (2010) 1.74
Mechanism underlying inhibition of intestinal apical Cl/OH exchange following infection with enteropathogenic E. coli. J Clin Invest (2007) 1.72